Table 1 Trials exploring ACE inhibitor dosing regimens in heart failure
From: Dose response of ACE inhibitors: implications of the SECURE trial
Trial | ACE-I regimens (daily doses) | Major findings |
|---|---|---|
NETWORK (n = 1532) | Enalapril 2.5 mg bid vs 5 mg bid vs 10 mg bid | No difference in hospitalizations for heart failure; trend |
| Â | Follow-up: 5.5 months | towards fewer deaths with increasing dose |
ATLAS (n = 3164) | Lisinopril 2.5-5 mg od vs 32.5-35 mg od | Trends towards reduced total and CV mortality and |
| Â | Follow-up:46 months | significant reduction in mortality and all-cause |
| Â | Â | hospitalizations for high-dose lisinopril |
CHIPS (n = 298) | Captopril 25 mg bid vs 50 mg bid | Trend towards reduced hospitalizations for heart failure and |
| Â | Follow-up: 2 years | towards reduced fatal and nonfatal cardiac events for |
| Â | Â | high-dose captopril |
HEDS (n = 248) | Enalapril 20 mg vs 60 mg | No significant differences in survival, clinical and |
| Â | Follow-up: 12 months | hemodynamic variables |